Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Boehringer Ingelheim
Dow
AstraZeneca
Merck

Last Updated: August 8, 2022

Investigational Drug Information for SM04690


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for SM04690?

SM04690 is an investigational drug.

There have been 11 clinical trials for SM04690. The most recent clinical trial was a Phase 3 trial, which was initiated on August 25th 2020.

The most common disease conditions in clinical trials are Osteoarthritis, Osteoarthritis, Knee, and Intervertebral Disc Degeneration. The leading clinical trial sponsors are Biosplice Therapeutics, Inc., Samumed LLC, and [disabled in preview].

There are ten US patents protecting this investigational drug and ninety-three international patents.

Recent Clinical Trials for SM04690
TitleSponsorPhase
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the KneeBiosplice Therapeutics, Inc.Phase 3
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy VolunteersBiosplice Therapeutics, Inc.Phase 1
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy VolunteersSamumed LLCPhase 1

See all SM04690 clinical trials

Clinical Trial Summary for SM04690

Top disease conditions for SM04690
Top clinical trial sponsors for SM04690

See all SM04690 clinical trials

US Patents for SM04690

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SM04690 See Plans and Pricing Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide Samumed, LLC (San Diego, CA) See Plans and Pricing
SM04690 See Plans and Pricing Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof Samumed, LLC (San Diego, CA) See Plans and Pricing
SM04690 See Plans and Pricing Treatment of osteoarthritis Samumed, LLC (San Diego, CA) See Plans and Pricing
SM04690 See Plans and Pricing Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-C]pyridin-2-yl)-1H-indazol-5-y- l)pyridin-3-yl)-3-methylbutanamide Samumed, LLC (San Diego, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SM04690

Drugname Country Document Number Estimated Expiration Related US Patent
SM04690 Australia AU2017274350 2036-06-01 See Plans and Pricing
SM04690 Brazil BR112018074725 2036-06-01 See Plans and Pricing
SM04690 Canada CA3026076 2036-06-01 See Plans and Pricing
SM04690 Chile CL2018003423 2036-06-01 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Boehringer Ingelheim
Dow
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.